PharmaSens and SiBionics partner on integrated patch for insulin delivery and glucose monitoring

Swiss medical device company PharmaSens has partnered with SiBionics to co-develop a single-patch system that combines insulin delivery with a continuous glucose monitor (CGM). The device, called the niia signature, is designed to simplify day-to-day diabetes management by integrating both functions into one wearable.

Under the deal, PharmaSens will combine its patch pump platform with SiBionics' biosensor technology.

The niia signature consists of two parts: a reusable component, designed to last two years, that houses the pump and CGM electronics, and a disposable piece that contains the insulin reservoir.

The device is intended to streamline setup by combining needle insertion and sensor placement into a single step, without the need for a syringe or separate inserter. Users can deliver bolus doses directly from the patch.

"This partnership marks a significant milestone toward realising our vision of a fully integrated, discreet, and intuitive insulin-therapy system," said PharmaSens CEO Marcel Both.

Development is being shared across both teams, with the project also focused on improving sustainability and long-term affordability through a semi-reusable design.

The collaboration follows continued activity in CGM development. In April, Dexcom received FDA clearance for a 15-day version of its G7 sensor, extending wear time from 10 to 15 days and offering slightly improved accuracy. The device is expected to launch in the US in the second half of the year, aimed at adults with Type 1 and insulin-treated Type 2 diabetes seeking fewer sensor changes and more consistent data.